ArticleBMJ (Clinical research ed.)2023

FDA approval, clinical trial evidence, efficacy, epidemiology, and price for non-orphan and ultra-rare, rare, and common orphan cancer drug indications: cross sectional analysis.

Thomas Michaeli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.